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BACKGROUND Activation of coagulation and thrombus formation
were considered as the initial steps in the mechanism of arterial
restenotic reaction, which could be potential targets for action of drug
eluting stent. Initial animal studies suggested that local delivery of
direct thrombin inhibitor, argatroban, suppressed platelet aggregation
and smooth muscle cell proliferation after balloon angioplasty.
Furthermore, several human trials of local delivery of this drug
demonstrated signiﬁcant reduction of angiographic restenosis rates.
Accordingly, argatoroban-eluting stent (JF-04) was developed, which
composed of cobalt-chromium thin strut (70mm) stent platform, car-
rier biodegradable polymer (50:50 poly DL-lactide-co-glycolide), and
argatroban. Drug elution was designed to complete within 40 days,
whereas polymer remained up to 9 months. The objective of this ﬁrst-
in-man study was to test the safety and feasibility of the JF-04 stent to
treat coronary lesions.
METHODS A total of 31 patients with either stable angina or unstable
angina, or silent myocardial ischemia, who had de novo coronary le-
sions (legion length: 6 - 26 mm, reference diameter: 2.5 - 3.5 mm by
visual estimation) were enrolled in the 7 Japanese sites. The lesions
were treated with the JF-04 stent after pre-dilatation. The primary
endpoint was set as angiographic in-stent late loss at 6-month after
implantation. The secondary endpoints consisted of angiographic,
intravascular ultrasound (IVUS), and optical coherence tomography
(OCT) representative parameters at 6-month and clinical outcomes at
9-month. Major adverse cardiac events (MACE) were deﬁned as
composites of cardiac death, any myocardial infarction, and target
vessel revascularization (TVR). Dual antiplatelet therapy was
mandated at least for 6-month after implantation.
RESULTS Procedural success was achieved in 100%. Angiographic in-
stent late loss was 1.01  0.48 mm and binary restenosis rate (in-
segment) was 29.0%. Other representative angiographic, IVUS, and
OCT parameters are summarized in Table. No stent thrombosis
occurred during 9-month follow-up period. Composite MACE rate was
12.9%, which was exclusively attributed to TVR.PreLesion length, mm 16.2  6.9
Reference vessel diameter, mm 2.98  0.58
AHA Type (A/ B1/ B2/ C), % 9.7/ 19.4/ 45.2/ 25.8PostIn-stent MLD, mm 2.73  0.48
6 month follow-upIn-stent MLD, mm 1.72  0.75
In-stent late loss, mm 1.01  0.48
In-segment late loss, mm 0.74  0.51
Angiographic binary restenosis, % 29.0Focal/Diffuse/Occlusive/Proliferative, % 3.2/ 19.4/ 3.2/ 3.2In-stent volume obstruction by IVUS, % 31.9  13.7
Uncovered strut rate by OCT, % 1.63  5.21
Malapposed strut rate by OCT, % 0.26  1.26CONCLUSIONS The ﬁrst-in-man study of biodegradable polymer-
based argatroban-eluting stent failed to show sufﬁcient inhibition of
neointimal hyperplasia in de novo native coronary lesions, which
resulted in relatively high restenosis rate as well as advanced angio-
graphic restenotic patterns. Estimated potential mechanisms of these
unfavorable outcomes included 1) limited capability inherent toargatroban for inhibition of cellular proliferation and 2) an unignorable
gap in duration of elution/ absorption between drug and polymer.
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BACKGROUND We compared the 3-year safety and efﬁcacy of the
newer generation zotarolimus-eluting Resolute Integrity stent (Med-
tronic) versus the everolimus-eluting Promus Element stent (Boston
Scientiﬁc) in all-comer patients, who were enrolled in the DUTCH
PEERS (TWENTE II) randomized trial (clinicaltrials.gov NCT01331707).
Newer generation permanent polymer-based drug-eluting stents
(DES) with ﬂexible designs show a high conformability to challenging
anatomies. Limited long-term data are available on the use of these
newer generation DES following percutaneous interventions for
complex and multiple coronary lesions.
METHODS In the randomized, multicenter, single-blinded, investi-
gator-initiated DUTCH PEERS trial, a total of 1,811 all-comer patients
were 1:1 randomly assigned to treatment with Resolute Integrity or
Promus Element stents. Patients diagnosed with stable angina as well
as acute coronary syndrome, any lesion type, and any number of le-
sions or vessels to be treated were enrolled at 4 study centers in the
Netherlands. The primary endpoint of target vessel failure (TVF) is a
composite of cardiac death, target vessel revascularization (TVR), or
myocardial infarction (MI). Study monitoring and clinical event
adjudication were performed by independent contract research or-
ganizations (Diagram, Zwolle, and Cardialysis, Rotterdam, the
Netherlands).
RESULTS A total of 1,293 (71.7%) patients were treated for complex
coronary lesions, while 455 (25.1%) patients were treated for multiple
target lesions. The 3-year incidence of TVF (primary endpoint) and
various secondary endpoints will be reported for both DES groups,
including the individual components of the primary endpoint. In
addition, the incidence of stent thrombosis, the composite endpoint
target lesion failure, and the more patient-oriented composite clinical
endpoints major adverse cardiac events and patient-oriented com-
posite endpoint will be presented.
CONCLUSIONS Three-year clinical outcome data of the randomized,
multicenter DUTCH PEERS trial will be reported at TCT 2015.
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